We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
RANDOX LABORATORIES

Download Mobile App





New Nanomechanical Technique for Fast, One-Step, Immune-Affinity Tests Rapidly Quantifies Transmissibility of COVID-19 Variants

By LabMedica International staff writers
Posted on 14 Oct 2021
Print article
Image: New Nanomechanical Technique for Fast, One-Step, Immune-Affinity Tests Rapidly Quantifies Transmissibility of COVID-19 Variants (Photo courtesy of Trinity College Dublin)
Image: New Nanomechanical Technique for Fast, One-Step, Immune-Affinity Tests Rapidly Quantifies Transmissibility of COVID-19 Variants (Photo courtesy of Trinity College Dublin)

A team of researchers has developed a new nanomechanical technique for fast, one-step, immune-affinity tests, which can quantify the immune response induced by different COVID-19 variants in serum.

The technique developed by researchers at Trinity College Dublin (Dublin, Ireland) provides a new tool for tracking infection immunity over time and for analysing new vaccine candidates. The team’s specific quantitative assay enables direct classification of variant-binding properties for screening emerging variants. The major advantage of the newly developed technique with respect to (existing, commonly used) ELISA tests is that while it is equally sensitive – with added single amino-acid resolution – and able to directly detect multiple variants by in situ differential analysis, it can also do so in a mere fraction of the time.

The researchers focused on COVID-19 variants of concern and their generated humoral immune response. Humoral immunity is an antibody-mediated response that occurs when foreign material is detected in the body. Given that the COVID-19 virus has developed substantial mutations in the spike protein, this can undermine the efficacy of current vaccines and monoclonal antibody therapies. The new technology developed by team of researchers can assist vaccine development studies in phase 1-3, with focus on comparing protection patterns and analyzing novel vaccine candidates.

“Our measurements match the statistical analysis of, for example, the transmissibility of the alpha-variant that can otherwise only be gained by analyzing the development of the disease proliferation within a population over weeks. We believe that this new technology can improve and speed up the public health guidance process,” said Professor Martin Hegner, Principal Investigator in the Trinity Centre for Research on Adaptive Nanostructures and Nanodevices (CRANN) and Trinity’s School of Physics. “The direct technique greatly simplifies the preparation protocol that in ELISA includes many washings and waiting steps, hence reducing the amount of consumables needed and thus the relative cost. It will therefore be well suited to use in emergency situations.”

Related Links:
Trinity College Dublin 

Gold Supplier
SARS-CoV-2/Flu A/B & RSV Test
RespiBio Panel 3 (RBRP3)
New
Static Concentrator
BJP 20 Static Concentrator
New
Modular Syndromic Testing System
QIAstat-Dx (DiagCORE) Analyzer
New
Respiratory Multiplex RT-PCR Kit
Respiratory Multiplex RT-PCR Kit

Print article

Channels

Hematology

view channel
Image: Psoriatic plaques, showing a silvery center surrounded by a reddened border (Photo courtesy of Jane Bianchi, BA)

Hematological Parameters Compared in Psoriasis Patients

Psoriasis is a chronic, immune-mediated disorder that can involve the skin and/or joints. Four clinical types of psoriasis are currently recognized: psoriasis vulgaris (PsV), pustular psoriasis (PP), erythrodermic... Read more

Microbiology

view channel
Illustration

Sysmex Inostics Launches New Ultra-Sensitive Leukemia Blood Test for Early Detection of Cancer Cells Following Initial Therapy

Sysmex Inostics (Baltimore, MD, USA) has developed a new CLIA-validated liquid biopsy test for the detection of Minimal Residual Disease (MRD) in Acute Myeloid Leukemia (AML) to better help in the fight... Read more

Technology

view channel
Image: QIAreach QuantiFERON-TB (Photo courtesy of QIAGEN N.V.)

Qiagen Launches Novel Tuberculosis Blood Test That Marks Quantum Leap from Traditional TB Skin Test

QIAGEN N.V. (Venlo, Netherlands) has announced the launch and CE marking of QIAreach QuantiFERON-TB test for tuberculosis (TB) infection, in order to help achieve global TB elimination targets by increasing... Read more

Industry

view channel
Image: GastroPanel Quick Test (Photo courtesy of Biohit Healthcare)

Biohit’s Innovative GastroPanel Quick Test Receives CE Mark

Biohit Healthcare’s (Helsinki, Finland) GastroPanel Quick Test, the latest innovation in its unique GastroPanel product family, is now CE marked. The GastroPanel Quick Test is intended for diagnosing... Read more
Copyright © 2000-2021 Globetech Media. All rights reserved.